Neurosense Therapeutics is trading 13.2% up at $3.95 after closing at $3.49 on October 13; the Nasdaq update is a plausible company-specific catalyst, but the move was not explicitly attributed to it. - Nasdaq scheduled the hearing for November 10, and shares are expected to keep trading while the appeal is pending. The company has regained compliance with the minimum bid-price rule. - It still faces a minimum-market-value listing deficiency, and the hearing outcome is uncertain. - The announcement also cited upcoming PrimeC and funding milestones; no after-hours trading-volume data was provided.